A vaccine targeting proteins of the flagella of Pseudomonas aeruginosa reduced the risk of initial infection in patients with cystic fibrosis, according to German researchers (Döring G et al. Proc Natl Acad Sci U S A. doi:10.1073/pnas.0702403104 [published online ahead of print June 21, 2007]).
Life-threatening chronic lung infections caused by P aeruginosa are the leading cause of morbidity and mortality for patients with cystic fibrosis, 80% of whom are infected with the pathogen. In the double-blind, randomized, placebo-controlled, phase 3 study, 37 of 189 patients (uninfected at baseline) who received all 4 vaccine doses developed P aeruginosa compared with 59 of 192 controls who received all 4 placebo injections.
Stephenson J. Pseudomonas. JAMA. 2007;298(3):277. doi:10.1001/jama.298.3.277-d